Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 04:00:00 2025-02-07 pm EST			5-day change	1st Jan Change
37.45 ^USD	-3.43%		-3.40%	+8.83%

Feb. 03	BofA Adjusts Price Target on Harmony Biosciences to $31 From $32	MT
Jan. 28	Harmony Biosciences Holdings Insider Sold Shares Worth $551,575, According to a Recent SEC Filing	MT

Harmony Biosciences Holdings, Inc., Q2 2024 Earnings Call, Aug 06, 2024

August 06, 2024 at 08:30 am EDT

Presentation Operator Message
Operator (Operator)

Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Harmony Biosciences Holdings, Inc.

BofA Adjusts Price Target on Harmony Biosciences to $31 From $32	Feb. 03	MT
Harmony Biosciences Holdings Insider Sold Shares Worth $551,575, According to a Recent SEC Filing	Jan. 28	MT
Harmony Biosciences Holdings Insider Sold Shares Worth $774,245, According to a Recent SEC Filing	Jan. 23	MT
Harmony Biosciences Holdings, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 11:15 AM	Jan. 15
Harmony Biosciences Reports Preliminary Q4, 2024 Net Product Revenue; 2025 Revenue Guidance Issued	Jan. 13	MT
Harmony Biosciences Holdings, Inc. Announces Preliminary, Unaudited Net Product Revenues for the Fourth Quarter and Full Year Ended December 31, 2024	Jan. 13	CI
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2025	Jan. 13	CI
HC Wainwright Initiates Harmony Biosciences at Buy With $75 Price Target	Dec. 17	MT
Harmony Biosciences Holdings Launches Secondary Common Stock Offering	24-10-30	MT
Harmony Biosciences Holdings, Inc., Q3 2024 Earnings Call, Oct 29, 2024	24-10-29
Harmony Biosciences Holdings Q3 Adjusted Earnings, Net Product Revenue Increase	24-10-29	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-10-29	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-29	CI
Harmony Biosciences Holdings, Inc. Re-Iterates Revenue Guidance for the Full Year 2024	24-10-29	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Reports Q3 EPS $1.03	24-10-29	MT
Harmony Biosciences Holdings, Inc. - Analyst/Investor Day	24-10-01
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says	24-09-10	MT
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target	24-09-10	MT
Mizuho Securities Adjusts Harmony Biosciences Price Target to $42 From $40, Maintains Outperform Rating	24-08-07	MT
Harmony Biosciences' Q2 Adjusted EPS, Revenue Rise; Shares Gain	24-08-06	MT
Harmony Biosciences Holdings, Inc., Q2 2024 Earnings Call, Aug 06, 2024	24-08-06
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-08-06	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q2 EPS $0.20, vs. Street Est of $0.12	24-08-06	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	24-08-06	CI